Epoprostenol (Flolan, Veletri)

Epoprostenol (Flolan, Veletri) is covered for pulmonary arterial hypertension (WHO Group I) and for compendial off‑label use in CTEPH but is not covered outside these approved/compendial indications and policy criteria. Coverage requires right‑heart catheterization confirmation of PAH, NYHA class III/IV (or class II with prior oral or inhaled/parenteral therapy), prescriber by/consult with a pulmonologist or cardiologist, idiopathic PAH vasodilator/CCB testing/trial criteria as applicable, dosing limits (PAH ≤100 ng/kg/min IV; CTEPH ≤45 ng/kg/min IV), approvals up to 12 months (≤30‑day short‑term supply if criteria/info insufficient), and reauthorization with documented continued benefit.

"Epoprostenol is a prostanoid vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise capacity."

Sign up to see full coverage criteria, indications, and limitations.